Nutra Pharma Drug Discovery Subsidiary, ReceptoPharm, has published positive results from its recent animal studies on the use of RPI-78 as a potential method for treating arthritis
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, in collaboration with Soochow University in China has published strong data from its recent animal studies on the use of RPI-78 (Cobratoxin) as a method for treating arthritis. RPI-78 is ReceptoPharm’s lead drug candidate currently being studied for the treatment of pain.
“While we were aware that RPI-78 had analgesic activity, the purpose of this study was to examine the specific anti-inflammatory effects of RPI-78 in an animal model of rheumatoid arthritis,” explained Dr. Paul Reid, CEO of ReceptoPharm. “The results demonstrate that RPI-78 acts by modulating the immune system’s production of inflammatory cytokines and lessens autoimmune damage to the joint,” he added.
The study was published in the February 2009 issue of Acta Pharmacologica Sinica, an international monthly publication and the official journal of the Chinese Pharmacological Society and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Recently, ReceptoPharm announced the filing of a patent application with the United States Patent and Trademark Office for the use of RPI-78 as a novel method for treating arthritis in humans.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). ReceptoPharm’s positive results from its study of RPI-78 (Cobratoxin) for the treatment of arthritis should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.